Maertens Johan, Lyon Sue
Department of Haematology, Universitaire Ziekenhuizen, Leuven, Belgium.
Freelance Medical Writer, London, UK.
Future Microbiol. 2017 Aug;12:839-842. doi: 10.2217/fmb-2017-0095. Epub 2017 Jul 26.
Report from the 43rd Annual Meeting of the European Society for Blood & Marrow Transplantation 2017, 26-29 March 2017, Marseille, France Cytomegalovirus (CMV) reactivation is a potentially life-threatening complication in immunocompromised recipients of hematopoietic cell transplantation (HCT). Its management was therefore a key topic for over 5000 delegates from 85 countries attending the 43rd Annual Meeting of the European Society for Blood & Marrow Transplantation 2017. The currently available anti-CMV armamentarium is seldom used to prevent CMV reactivation due to the associated myelosuppression and renal toxicity. Following HCT, CMV reactivation is generally managed pre-emptively using sensitive assays for early detection of viral DNA (and to a lesser extent antigenemia) and, where necessary, treatment with antiviral drugs with the aim of preventing CMV disease. However, any degree of CMV reactivation increases the risk of mortality, and novel antiviral therapies may offer the possibility of prophylaxis to prevent CMV reactivation and improve survival after HCT.
2017年欧洲血液与骨髓移植学会第43届年会报告，2017年3月26 - 29日，法国马赛
巨细胞病毒（CMV）再激活是造血细胞移植（HCT）免疫受损受者中一种潜在的危及生命的并发症。因此，其管理是参加2017年欧洲血液与骨髓移植学会第43届年会的来自85个国家的5000多名代表的一个关键议题。由于相关的骨髓抑制和肾毒性，目前可用的抗CMV药物很少用于预防CMV再激活。HCT后，CMV再激活通常通过使用敏感检测方法早期检测病毒DNA（以及程度较轻的病毒血症）进行抢先管理，必要时使用抗病毒药物治疗，目的是预防CMV疾病。然而，任何程度的CMV再激活都会增加死亡风险，新型抗病毒疗法可能提供预防CMV再激活和改善HCT后生存率的预防可能性。
